D espite the efficacy of conventional antipsychotics in ameliorating the positive symptoms of schizophrenia, up to 30% of individuals with schizophrenia fail to respond to these medications (1) . Further, 20% to 30% of patients experience a relapse, despite adequate maintenance treatment with conventional antipsychotic agents (2, 3) . The second generation antipsychotics, the atypicals, were developed to address the shortcomings of the typical medications: limited efficacy, possible worsening of negative symptoms, and troubling side effects (4).
The atypical antipsychotic medications have contributed significantly to the treatment of schizophrenia (5) (6) (7) (8) (9) (10) (11) (12) (13) . For several reasons, however, published research on the efficacy of antipsychotic medications is limited. First, most clinical trials have been carried out in hospital settings (5) , while most patients with schizophrenia are treated in the community. Second, the published studies provide evidence for the short-term efficacy of atypical, compared with typical, antipsychotics. Long-term studies are particularly relevant to patients with schizophrenia, because it is a chronic disorder (14) . Researchers and mental health professionals have highlighted the need for investigations that go beyond tightly controlled efficacy trials and do field studies performed under real-world conditions (5, 15) .
With these issues in mind, we set out to examine the effects on a sample of community-based outpatients with schizophrenia of switching from typical to atypical antipsychotic medications.
Method

Subjects
All 43 subjects who completed the study are patients of an urban, community-based treatment and rehabilitation program in Ontario, the Hamilton Program for Schizophrenia (HPS). The program's patients have a diagnosis of schizophrenia as a criterion for admission (16) . Table 1 presents relevant clinical and demographic information for the sample.
Inclusion criteria for this study were based on 3 parameters. First, patients had to remain in the program for 4 consecutive years during the study period. Second, patients completed the Positive and Negative Syndrome Scale (PANSS) (1) and Quality of Life Interview (QOL) (17) and agreed that these scores could be available for evaluation purposes each year. (All participants provided informed consent before their PANSS and QOL interviews were conducted.) Third, patients had to have taken a single typical antipsychotic for at least 2 consecutive years before switching and a single atypical medication for 2 consecutive years after switching. We selected a 2-year period because of the relevance of long-term studies to patients with chronic disorders who are treated in the community. Patients with comorbid conditions (for example, other psychiatric diagnoses or substance abuse) were not excluded from the study.
Measures
PANSS.
The scale assesses positive and negative symptoms and general psychopathology (1) . We assessed participants annually and used the PANSS raw scores in the statistical analysis (18) .
Quality of Life. The Lehman QOL (17) was used as the quality-of-life measure. This scale uses patients' own ratings along several dimensions of life and has been shown to be relevant to people with a psychiatric disability who are living in the community (19) . In this study, we used the scale's main quality-of-life measure, the subjective global satisfaction scale.
Management Information System (MIS).
Service utilization is recorded routinely as part of the HPS management information system. The variables examined in this study included case-management time, crisis time (that is, minutes of emergency case-management time provided over a 2-year period), and psychiatric hospitalization days.
Procedure
Yearly PANSS and QOL interviews were gathered from 1992-3 until the end of the study period in 1999. A trained rater who was independent of the treating psychiatrists and blind to patient medication status conducted the assessment.
The treating psychiatrist ordered the patient's medication in the clinical record, and this information was subsequently extracted by the researchers. The 2 program psychiatrists were solely responsible for prescribing medications and dosages. They based their decisions on patient symptoms, clinical presentation, side effects, and response.
Patients were switched to clozapine, risperidone, or olanzapine if they were not responding optimally to, or were experiencing side effects from, the conventional antipsychotics or if the treating psychiatrist agreed to their request to switch medications. Reflecting the high incidence of comorbidity, this study included patients who received medications (for example, antidepressants, anxiolytics, and mood stabilizers) for conditions other than psychosis. Table 2 lists the medications prescribed in the preswitch (typical antipsychotic) and postswitch (atypical antipsychotic) years.
Statistical Analyses
We analyzed the PANSS (Positive Symptoms, Negative Symptoms, and General Psychopathology) and QOL measures, using a 2-way factorial ANOVA with independent variables of time (first and second year on the drug) and drug type (typical vs atypical). Clinical response rates for treatment with typical antipsychotics (that is, improvement from preswitch year 1 to year 2) were compared with those for treatment with atypicals (that is, improvement from year 2 to year 4), using a chi-squared test. The Management Information System (MIS) data were collapsed for the first 2 years (preswitch) and again for the final 2 years (postswitch). The MIS pre-and postswitch data were then analyzed using t-tests. Because the study hypothesized a priori improvements with the switch to atypicals, 1-tailed tests were applied as indicated; all other P-values are 2-tailed.
Results
Symptom Outcomes (PANSS)
Symptom and mental illness-related outcomes assessed using the PANSS revealed a significant main effect for medication for positive symptoms ( F = 2.91, P < 0.05, 1-tailed).
Switching medications was not associated just with significant improvements in positive symptoms in the first year after the switch: this association was maintained throughout the second postswitch year.
With regard to negative symptoms, ANOVA analysis did not find a statistically significant effect of switching from typical to atypical medications. The study sample scored among the bottom 16% of schizophrenia patients on the PANSS negative scale according to reported norms (18) , suggesting clinical stability and relative absence of negative symptoms.
Scores on the general psychopathology scale of the PANSS indicated significant patient improvement in this domain, including ameliorated symptoms of anxiety and depression when subjects were switched from typical to atypical antipsychotics (F = 6.73, P = 0.01). It appeared that improvements in general psychopathology were seen in the first postswitch year and were sustained throughout the second year of the study.
Analysis of individual PANSS total scores indicated that significantly more patients demonstrated a clinical response after they were switched to the atypical medications. Fifteen patients demonstrated a clinical response, defined as a 20% reduction in these scores, whereas only 4 patients demonstrated a clinical response prior to switching (P 2 = 8.17, P < 0.005).
Functional Outcomes (Quality of Life)
Analysis of the Lehman QOL data indicated that, after subjects were switched from typical to atypical medications, their general sense of satisfaction with their own life situation improved significantly (F = 3.21, P < 0.038, 1-tailed) (see Figure 1) .
Resource Utilization Outcomes (MIS Data)
In terms of case-management service utilization, following the switch there was a statistically significant 17% reduction in the need for intensive case-management services, from a mean of 55.0 hours (SD 32.3) for the 2 years before the switch to 45.6 hours (SD 24.3) for the 2 years after the switch (t = 2.41, P < 0.02). This represents a total saving of approximately 11.5 weeks of cumulative staff time.
Following the switch to atypical medications, there was a statistically significant 43% reduction in crisis time required by patients, from 4.3 hours (SD 5.3) to 2.5 hours (SD 3.5) (t = 2.55, P < 0.02), representing a total agency saving of more than 75 hours.
Finally, switching to atypical medications provided a significant 99% reduction in hospitalization days, from 6.7 (SD 15.9) to almost none (0.07, SD 0.5) (t = 2.74, P < 0.009). Prior to switching to an atypical medication, 60% of subjects were prescribed an injectible medication.
Discussion
We observed additional long-term benefits in the form of diminished positive symptoms, reduced general psychopathology, and improved quality of life when individuals with schizophrenia receiving community-based treatment were switched from typical to atypical antipsychotic medications for reasons often encountered in this setting. Patients also demonstrated significantly reduced days spent in hospital as well as decreased requirements for case-management and crisis services. Overall efficacy was perhaps most evident in the finding that, following the switch to atypical antipsychotic medications, significantly more individuals met the specific criteria for demonstrating a clinical response. Our findings confirm that outpatients who have responded less than optimally to treatment with typical antipsychotics can benefit from a switch to olanzapine, risperidone, or clozapine. This work extends the findings of previous controlled drug trials by providing efficacy data over an extended period of time and under conditions that most closely correspond to real-world clinical decision making, tailoring treatment to individual needs.
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Conclusions :
Chez des patients stables souffrant de schizophrénie dans un cadre de monde réel, le passage à un antipsychotique atypique peut se traduire par une amélioration significative et soutenue de la réaction clinique et de la qualité de vie ainsi que par un besoin moindre d'hospitalisation et de soutien communautaire.
